Eden Research plc Completion of Conditional Placing (7388O)

TIDMEDEN

RNS Number : 7388O

Eden Research plc

05 October 2023

5 October 2023

Eden Research plc

("Eden", the "Group" or the "Company")

Completion of Conditional Placing

Eden Research plc (AIM: EDEN), the AIM-quoted company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, provides an update on the proposed completion of its Conditional Placing, as originally announced on 28 July 2023.

Eden is pleased to announce that 129,230,769 Ordinary Shares will be issued via the Conditional Placing, raising GBP8.4 million (before expenses). This includes subscriptions for 7,692,307 Ordinary Shares more than the minimum announced at the time of the initial announcement, raising a further GBP0.5 million. Consequently, a total of GBP9.9 million (before expenses) has been raised pursuant to the Firm Capital Raising, the Retail Offer and the Conditional Placing.

Application has been made for 129,230,769 Conditional Placing Shares to be admitted to trading on AIM ("Admission"). Admission is expected to take place at 8.00 a.m. on 6 October 2023.

Following the Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 533,352,523 with each Ordinary Share carrying the right to one vote. There are no Ordinary Shares held in treasury and therefore the total number of voting rights in the company is expected to be 533,352,523. The above figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meaning given to them in the placing and retail offer announcement dated 28 July 2023, unless otherwise defined in this announcement.

For further information, please contact:

 
 Eden Research plc                               www.edenresearch.com 
 
 Sean Smith / Alex Abrey 
 
  Cavendish Securities Plc (Nominated advisor 
  and broker) 
 Giles Balleny (Corporate Finance) / Michael 
  Johnson (Sales)                                020 7397 8900 
 
 
   Hawthorn Advisors (Financial PR) 
 Simon Woods                                     [e-mail] 
  Felix Meston 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEMIBPTMTMMBFJ

(END) Dow Jones Newswires

October 05, 2023 02:00 ET (06:00 GMT)